By Professor Richard John Epstein

Journal articles

Tan E; Lim S; Lamont D; Epstein R; Lim D; Lin FPY, 2024, 'Development and validation of a deep learning model for improving detection of nonmelanoma skin cancers treated with Mohs micrographic surgery', JAAD International, 14, pp. 39 - 47, http://dx.doi.org/10.1016/j.jdin.2023.10.007

Lin FP-Y; Joshua AM; Epstein RJ, 2023, 'Machine learning prediction of patient-reported outcomes associated with systemic therapy from medical records.', Journal of Clinical Oncology, 41, pp. e13564 - e13564, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e13564

Tempero MA; Pelzer U; O'Reilly EM; Winter J; Oh DY; Li CP; Tortora G; Chang HM; Lopez CD; Bekaii-Saab T; Ko AH; Santoro A; Park JO; Noel MS; Frassineti GL; Shan YS; Dean A; Riess H; Van Cutsem E; Berlin J; Philip P; Moore M; Goldstein D; Tabernero J; Li M; Ferrara S; Le Bruchec Y; Zhang G; Lu B; Biankin AV; Reni M; Epstein R; Vasey P; Shapiro J; Burge M; Chua YJ; Harris M; Pavlakis N; Tebbutt N; Prager G; Dittrich C; Längle F; Philipp-Abbrederis K; Greil R; Stöger H; Girschikofsky M; Kuehr T; Van Laethem JL; Laurent S; Dhani N; Ko YJ; Dowden S; Kavan P; Tehfe MÉ; Kubala E; Kohoutek M; Pfeiffer P; Yilmaz M; Parner V; Salminen T; Soveri LM; Korkeila E; Osterlund P; Taieb J; Tougeron D; Artru P; Caroli-Bosc FX; Guimbaud R; Turpin A; Walter T; Bachet JB; Kunzmann V; Kreth F; Block A; Venerito M; Oettle H; Karthaus M; Trojan J; Folprecht G; Lerch M; Kullmann F; Reiser M; Heinemann V; Wörns MA; Schulz H; Garlipp B; Yau T; Chan LS; Juhasz B; Landherr L; Pinter T; Bodoky G; Kahán Z; McDermott R; Power D; Gianni L; Siena S; Milella M; Falcone A; Berardi R, 2023, 'Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial', Journal of Clinical Oncology, 41, pp. 2007 - 2019, http://dx.doi.org/10.1200/JCO.22.01134

Epstein RJ; Lin FPY; Brink RA; Blackburn J, 2023, 'Synonymous alterations of cancer-associated Trp53 CpG mutational hotspots cause fatal developmental jaw malocclusions but no tumors in knock-in mice', PLoS ONE, 18, http://dx.doi.org/10.1371/journal.pone.0284327

Epstein RJ; Gu Y; Lin FPY, 2023, 'Can cancer go green? It’s up to us', Frontiers in Oncology, 13, http://dx.doi.org/10.3389/fonc.2023.1074091

Epstein RJ, 2023, 'To find fault is easy, to find no-fault is fair.', Future Healthc J, 10, pp. 85 - 89, http://dx.doi.org/10.7861/fhj.2022-0049

Po-Yen Lin F; Salih OSM; Scott N; Jameson MB; Epstein RJ, 2022, 'Development and Validation of a Machine Learning Approach Leveraging Real-World Clinical Narratives as a Predictor of Survival in Advanced Cancer', JCO clinical cancer informatics, 6, pp. e2200064, http://dx.doi.org/10.1200/CCI.22.00064

Epstein RJ, 2021, 'The secret identities of TMPRSS2: Fertility factor, virus trafficker, inflammation moderator, prostate protector and tumor suppressor', Tumor Biology, 43, pp. 159 - 176, http://dx.doi.org/10.3233/TUB-211502

Epstein RJ; Tian LJ; Gu YF, 2021, '2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology', Journal of Oncology, 2021, http://dx.doi.org/10.1155/2021/9955456

Gu YF; Lin FP; Epstein RJ, 2021, 'How aging of the global population is changing oncology', ecancermedicalscience, 15, http://dx.doi.org/10.3332/ecancer.2021.ed119

Lami H; Epstein RJ; Cherepanoff S; Conway RM, 2020, 'Effective conservative management of locally advanced conjunctival melanoma using initial systemic therapy', Clinical and Experimental Ophthalmology, 48, pp. 402 - 404, http://dx.doi.org/10.1111/ceo.13691

Sternberg CN; Saad F; Graff JN; Peer A; Vaishampayan UN; Leung E; Rosenbaum E; Gurney H; Epstein RJ; Davis ID; Wu B; Trandafir L; Wagner VJ; Hussain M, 2020, 'A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer', Annals of Oncology, 31, pp. 257 - 265, http://dx.doi.org/10.1016/j.annonc.2019.10.025

Vasista A; Stockler M; Martin A; Pavlakis N; Sjoquist K; Goldstein D; Gill S; Jain V; Liu G; Kannourakis G; Kim YH; Nott L; Snow S; Burge M; Harris D; Jonker D; Chua YJ; Epstein R; Bonaventura A; Kiely B, 2019, 'Accuracy and Prognostic Significance of Oncologists’ Estimates and Scenarios for Survival Time in Advanced Gastric Cancer', Oncologist, 24, pp. e1102 - e1107, http://dx.doi.org/10.1634/theoncologist.2018-0613

Lin FP-Y; Jameson MB; Epstein RJ, 2019, 'Predicting survival in advanced cancers by applying machine learning to clinical narratives.', Journal of Global Oncology, 5, pp. 32 - 32, http://dx.doi.org/10.1200/jgo.2019.5.suppl.32

Young FP; Ende D; Epstein RJ, 2019, 'Beyond BCG: The approaching era of personalised bladder-sparing therapies for non-muscle-invasive urothelial cancers', Future Oncology, 15, pp. 409 - 420, http://dx.doi.org/10.2217/fon-2018-0565

Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM, 2019, 'Results of a Prospective Phase 2 Pilot Trial of ¹⁷⁷ Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression', Clinical Genitourinary Cancer, 17, pp. 15 - 22, http://dx.doi.org/10.1016/j.clgc.2018.09.014

Emmett L; Yin C; Crumbaker M; Hruby G; Kneebone A; Epstein R; Nguyen Q; Hickey A; Ihsheish N; O'Neill G; Horvath L; Chalasani V; Stricker P; Joshua AM, 2019, 'Rapid modulation of PSMA expression by androgen deprivation: Serial ⁶⁸Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade', Journal of Nuclear Medicine, 60, pp. 950 - 954, http://dx.doi.org/10.2967/jnumed.118.223099

Francis PA; Pagani O; Fleming GF; Walley BA; Colleoni M; Láng I; Gómez HL; Tondini C; Ciruelos E; Burstein HJ; Bonnefoi HR; Bellet M; Martino S; Geyer CE; Goetz MP; Stearns V; Pinotti G; Puglisi F; Spazzapan S; Climent MA; Pavesi L; Ruhstaller T; Davidson NE; Coleman R; Debled M; Buchholz S; Ingle JN; Winer EP; Maibach R; Rabaglio-Poretti M; Ruepp B; Di Leo A; Coates AS; Gelber RD; Goldhirsch A; Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group , 2018, 'Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.', N Engl J Med, 379, pp. 122 - 137, http://dx.doi.org/10.1056/NEJMoa1803164

Smith MR; Saad F; Chowdhury S; Oudard S; Hadaschik BA; Graff JN; Olmos D; Mainwaring PN; Lee JY; Uemura H; Lopez-Gitlitz A; Trudel GC; Espina BM; Shu Y; Park YC; Rackoff WR; Yu MK; Small EJ, 2018, 'Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer', New England Journal of Medicine, 378, pp. 1408 - 1418, http://dx.doi.org/10.1056/nejmoa1715546

Lin FP; Epstein RJ; Groza T; Kocbek S; Antezana E, 2018, 'Cancer care treatment outcome ontology: A novel computable ontology for profiling treatment outcomes in patients with solid tumors', JCO Clinical Cancer Informatics, 2018, pp. 1 - 14, http://dx.doi.org/10.1200/CCI.18.00026

Lin FPY; Pokorny A; Teng C; Epstein RJ, 2017, 'TEPAPA: A novel in silico feature learning pipeline for mining prognostic and associative factors from text-based electronic medical records', Scientific Reports, 7, pp. 6918, http://dx.doi.org/10.1038/s41598-017-07111-0

Fazekas-Lavu M; Parker A; Spigelman AD; Scott RJ; Epstein RJ; Jensen M; Samaras K, 2017, 'Thyroid cancer in a patient with lynch syndrome – case report and literature review', Therapeutics and Clinical Risk Management, 13, pp. 915 - 918, http://dx.doi.org/10.2147/TCRM.S121812

Epstein RJ; Lin FP, 2017, 'Cancer and the omics revolution', Australian Family Physician, 46, pp. 189 - 193

Vasista A; Martin A; Pavlakis N; Sjoquist K; Snow S; Jonker D; Chua YJ; Epstein R; Bonaventura A; Khasraw M; Varma SC; Singhal N; Ransom DT; Aubin F; Burkes R; Lim H; Lemay F; Begbie S; Stockler MR; Kiely B, 2017, 'Accuracy and prognostic significance of oncologists’ estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer', Annals of Oncology, 28, pp. v226 - v227, http://dx.doi.org/10.1093/annonc/mdx369.050

Epstein RJ, 2016, 'Be careful what you wish for', Medical Journal of Australia, 205, pp. 521 - 522.e1, http://dx.doi.org/10.5694/MJA16.00836

Lin FPY; Pokorny A; Teng C; Dear R; Epstein RJ, 2016, 'Computational prediction of multidisciplinary team decision-making for adjuvant breast cancer drug therapies: A machine learning approach', BMC Cancer, 16, pp. 929, http://dx.doi.org/10.1186/s12885-016-2972-z

Blackburn J; Roden DL; Ng R; Wu J; Bosman A; Epstein RJ, 2016, 'Damage-inducible intragenic demethylation of the human TP53 tumor suppressor gene is associated with transcription from an alternative intronic promoter', Molecular Carcinogenesis, 55, pp. 1940 - 1951, http://dx.doi.org/10.1002/mc.22441

Choueiri TK; Escudier B; Powles T; Mainwaring PN; Rini BI; Donskov F; Hammers H; Hutson TE; Lee J-L; Peltola K; Roth BJ; Bjarnason GA; Géczi L; Keam B; Maroto P; Heng DYC; Schmidinger M; Kantoff PW; Borgman-Hagey A; Hessel C; Scheffold C; Schwab GM; Tannir NM; Motzer RJ; METEOR Investigators , 2015, 'Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.', N Engl J Med, 373, pp. 1814 - 1823, http://dx.doi.org/10.1056/NEJMoa1510016

Zheng S; Chan H; Epstein RJ; Joseph JE, 2015, 'Resolution of paraneoplastic immune thrombocytopenia following everolimus treatment for metastatic renal cell carcinoma', Internal Medicine Journal, 45, pp. 666 - 669, http://dx.doi.org/10.1111/imj.12779

Epstein RJ, 2015, 'A periodic table for cancer', Future Oncology, 11, pp. 785 - 800, http://dx.doi.org/10.2217/fon.14.315

Francis PA; Regan MM; Fleming GF; Láng I; Ciruelos E; Bellet M; Bonnefoi HR; Climent MA; Da Prada GA; Burstein HJ; Martino S; Davidson NE; Geyer CE; Walley BA; Coleman R; Kerbrat P; Buchholz S; Ingle JN; Winer EP; Rabaglio-Poretti M; Maibach R; Ruepp B; Giobbie-Hurder A; Price KN; Colleoni M; Viale G; Coates AS; Goldhirsch A; Gelber RD; SOFT Investigators ; International Breast Cancer Study Group , 2015, 'Adjuvant ovarian suppression in premenopausal breast cancer.', N Engl J Med, 372, pp. 436 - 446, http://dx.doi.org/10.1056/NEJMoa1412379

Epstein RJ, 2015, 'PERSONAL VIEW "By the way doctor, I've booked an African safari after my next chemo"', BMJ-BRITISH MEDICAL JOURNAL, 350, http://dx.doi.org/10.1136/bmj.g7822

Ding P; Tai J; Manders P; Stone E; Ho B; Epstein R, 2015, '500P Dependence of fluorodeoxyglucose avidity on tumour size in non-small cell lung cancer', Annals of Oncology, 26, pp. ix153 - ix153, http://dx.doi.org/10.1093/annonc/mdv534.04

Wong H; Lau S; Cheung P; Wong TT; Parker A; Yau T; Epstein RJ, 2014, 'Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: Implications for tumor biology and adjuvant therapy', BMC Cancer, 14, http://dx.doi.org/10.1186/1471-2407-14-826

Pagani O; Regan MM; Walley BA; Fleming GF; Colleoni M; Láng I; Gomez HL; Tondini C; Burstein HJ; Perez EA; Ciruelos E; Stearns V; Bonnefoi HR; Martino S; Geyer CE; Pinotti G; Puglisi F; Crivellari D; Ruhstaller T; Winer EP; Rabaglio-Poretti M; Maibach R; Ruepp B; Giobbie-Hurder A; Price KN; Bernhard J; Luo W; Ribi K; Viale G; Coates AS; Gelber RD; Goldhirsch A; Francis PA; TEXT and SOFT Investigators ; International Breast Cancer Study Group , 2014, 'Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.', N Engl J Med, 371, pp. 107 - 118, http://dx.doi.org/10.1056/NEJMoa1404037

Zhang Q; Leung R; Wong H; Chiu J; Chu KW; Poon J; Epstein RJ; Kwong YL; Yau T, 2014, 'Comparison of cetuximab and bevacizumab as first-line treatment in KRAS wild type advanced colorectal cancer patients: a retrospective analysis', EUROPEAN JOURNAL OF CANCER, 50, pp. S12 - S12, http://dx.doi.org/10.1016/S0959-8049(14)70040-1

Connolly K; Manders P; Earls P; Epstein RJ, 2014, 'Papillomavirus-associated squamous skin cancers following transplant immunosuppression: One Notch closer to control', Cancer Treatment Reviews, 40, pp. 205 - 214, http://dx.doi.org/10.1016/j.ctrv.2013.08.005

Connolly K; Brungs D; Szeto E; Epstein RJ, 2014, 'Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF^V600E-mutant metastatic colorectal carcinoma', Current Oncology, 21, http://dx.doi.org/10.3747/co.21.1661

Quah XM; Conway RM; Madigan MC; Epstein RJ, 2014, 'Emerging strategies for therapeutic targeting of the tumour microenvironment', Cancer Forum, 38, pp. 133 - 137

Brungs D; Chen J; Masson P; Epstein RJ, 2014, 'Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: Results from a systematic review and meta-analysis', Prostate Cancer and Prostatic Diseases, 17, pp. 105 - 111, http://dx.doi.org/10.1038/pcan.2014.10

Epstein RJ, 2013, 'The unpluggable in pursuit of the undruggable: Tackling the dark matter of the cancer therapeutics universe', Frontiers in Oncology, 3 DEC, http://dx.doi.org/10.3389/fonc.2013.00304

Epstein RJ, 2013, 'Has discovery-based cancer research been a bust?', Clinical and Translational Oncology, 15, pp. 865 - 870, http://dx.doi.org/10.1007/s12094-013-1071-8

Zhao Y; Epstein RJ, 2013, 'Conserved nonsense-prone CpG sites in apoptosis-regulatory genes: Conditional stop signs on the road to cell death', Evolutionary Bioinformatics, 2013, pp. 275 - 283, http://dx.doi.org/10.4137/EBO.S11759

Epstein CR; Epstein RJ, 2013, 'Death in The New York Times: the price of fame is a faster flame', QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 106, pp. 517 - 521, http://dx.doi.org/10.1093/qjmed/hct077

Chiu J; Tang V; Leung R; Wong H; Chu KW; Poon J; Epstein RJ; Yau T, 2013, 'Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis', Asian Pacific Journal of Cancer Prevention, 14, pp. 6585 - 6590, http://dx.doi.org/10.7314/APJCP.2013.14.11.6585

Brungs D; Sze V; Emmett L; Epstein RJ, 2013, 'Complete Radiologic Response of Bulky Cerebral Metastases From Newly Diagnosed HER2-Positive Breast Cancer to Upfront Trastuzumab-Based Chemotherapy.', World J Oncol, 4, pp. 122 - 125, http://dx.doi.org/10.4021/wjon639w

Epstein RJ; Epstein SD, 2012, 'Modernising the regulation of medical migration: moving from national monopolies to international markets.', BMC medical ethics, 13, pp. 26, http://dx.doi.org/10.1186/1472-6939-13-26

Wong H; Lau S; Leung R; Chui J; Cheung P; Wong TT; Richard E; Yau T, 2012, 'Co-existing ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer', Medical Oncology, 29, pp. 1536 - 1542, http://dx.doi.org/10.1007/s12032-011-0082-y

Campone M; Bondarenko I; Brincat S; Hotko Y; Munster PN; Chmielowska E; Fumoleau P; Ward RL; Bardy-Bouxin N; Leip E; Turnbull K; Zacharchuk C; Epstein RJ, 2012, 'Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy', Annals of Oncology, 23, pp. 610 - 617, http://dx.doi.org/10.1093/annonc/mdr261

Wong H; Leung R; Lau S; Chiu J; Cheung P; Wong T; Liang R; Epstein R; Yau T, 2011, 'Presence of an in-situ component predicts reduced tumor aggressiveness in luminal subtype of invasive breast cancer', BREAST, 20, pp. S39 - S39, http://dx.doi.org/10.1016/S0960-9776(11)70124-2

Back to profile page